Overview
CJC-1295 with DAC is a modified growth-hormone-releasing hormone analogue studied in laboratory models of GHRH receptor activity, peptide half-life extension, and endocrine signalling pathways.
Research context
The DAC component is discussed in relation to albumin-binding and extended peptide exposure models. This listing is kept separate from CJC-1295 no-DAC because the analytical identity, salt form, and research context are different and should be verified against the current batch COA.
Analytical focus
- GHRH receptor pathway and modified GRF analogue research.
- DAC-linked albumin-binding and peptide half-life extension models.
- Comparison with CJC-1295 no-DAC, Sermorelin, and Tesamorelin literature.
- Batch-level verification of exact identity, sequence notation, and purity.
Batch documentation
Review the label and latest COA for batch-specific identity, purity, physical appearance, salt form, and analytical documentation before planning any controlled research workflow.
References and literature starting points
Research-use notice: Supplied strictly for lawful research, laboratory, analytical, educational, or R&D purposes where permitted by applicable law. Not for human or animal use, consumption, diagnosis, treatment, food, supplement, cosmetic, veterinary, or similar end use.




